EMPR

Published September 10, 2026 · Updated September 11, 2026

LSD Derivative DT120 Earns FDA Breakthrough Status for MDD - MPR - eMPR.com

Read the full story at EMPR

The FDA granted Breakthrough Therapy designation to DT120 (lysergide ODT) for major depressive disorder based on positive phase 3 Emerge trial.